Skip to main content
21747 search results for:

NSCLC 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 18-04-2024 | Online First

    Radiotherapie plus Durvalumab beim lokal fortgeschrittenen NSCLC: die DOLPHIN-Studie

    Die PACIFIC-Studie prüfte als erste Studie die Kombination aus Radiochemo- und Immuntherapie bei Patienten mit NSCLC im UICC-Stadium III mit großem Erfolg. Die Gabe von Durvalumab nach vorheriger RCT verbesserte nicht nur das PFS, sondern auch das …

  2. 09-04-2024 | Adverse Effects of Cancer Therapy | News | Article

    Alectinib may cause androgen deficiency in men with NSCLC

    An Italian study suggests the need to monitor for androgen deficiency in men with ALK -positive, advanced NSCLC receiving alectinib.

  3. Open Access 01-06-2024 | NSCLC | OriginalPaper

    A2AR-mediated CXCL5 upregulation on macrophages promotes NSCLC progression via NETosis

    Tumor-associated macrophages (TAMs) are abundant in tumors and interact with tumor cells, leading to the formation of an immunosuppressive microenvironment and tumor progression. Although many studies have explored the mechanisms underlying TAM …

  4. Open Access 01-06-2024 | NSCLC | OriginalPaper

    T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC

    Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of newly diagnosed lung cancer cases annually [ 1 – 3 ]. Surgical resection with curative intent remains the …

  5. Open Access 01-12-2024 | NSCLC | OriginalPaper

    The value of lung function assessment and Testin expression detection in clinicopathological features and prognosis of NSCLC patients

    Lung cancer is the dominant cause of cancer-related death worldwide, with NSCLC accounting for nearly 85% [ 1 ]. Smoking, airway inflammation and air pollution are the common pathogenic factors of NSCLC [ 2 ]. Airway obstruction such as chronic …

  6. 23-03-2024 | NSCLC | ReviewPaper

    Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC

    Despite targeted therapy and immunotherapy being recognized as established frontline treatments for advanced non-small cell lung cancer (NSCLC), the unavoidable development of resistance and disease progression poses ongoing challenges.

  7. Open Access 01-12-2024 | NSCLC | OriginalPaper

    Circ-10720 as a ceRNA adsorbs microRNA-1238 and modulates ZEB2 to boost NSCLC development by activating EMT

    Lung cancer is the most prevalent cancer [ 1 ]. The mortality of lung cancer has decreased slightly over the past few years, but the number of deaths in 2017 still exceeded that of prostate, breast, brain, and colorectal cancers combined [ 2 ]. The …

  8. 16-04-2024 | NSCLC | Online First

    Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

    Lung cancer had a high incidence and mortality in the world. In the cause of cancer death in men and women is the location of the first and second respectively [ 1 ]. Adenocarcinoma accounted for most of non-small cell lung cancer, and the major …

  9. Open Access 11-03-2024 | Osimertinib | Letter

    Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

    This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the epidermal growth factor receptor (EGFR) on cancer cells, causing cancer cell death and tumor …

  10. Open Access 03-11-2023 | Radiotherapy | ReviewPaper

    Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions

    Non-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over …

  11. Open Access 01-12-2024 | Tuberculosis | OriginalPaper

    Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients

    Tuberculosis (TB) is a highly contagious respiratory disease that presents a grave global threat. The 2022 report from the World Health Organization (WHO) reveals an unsettling change in the TB incidence trend, which had been declining over the …

  12. 14-03-2024 | NSCLC | News | Article

    Trial reassures on SABR use in NSCLC patients with ILD

    Phase 2 data point to a favorable benefit–risk balance of stereotactic ablative radiotherapy in many patients with early-stage NSCLC and interstitial lung disease.

  13. 25-10-2023 | NSCLC | Expert Interview | Article

    Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs

    Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this vodcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint. 

    Illumina, Inc., and Eli Lilly and Company
  14. Open Access 19-04-2024 | NSCLC | Online First

    Correction to: Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

  15. Open Access 01-12-2024 | NSCLC | OriginalPaper

    Smoking behavior associated upregulation of SERPINB12 promotes proliferation and metastasis via activating WNT signaling in NSCLC

    Smoking is still believed to be one of the most important reasons for the initiation and progression of malignant cancer, especially for Non-small cell lung cancer (NSCLC) [ 1 – 3 ]. The overall survival of NSCLC was less than 30% [ 4 ]. Smoking is …

  16. Open Access 01-05-2024 | NSCLC | OriginalPaper

    circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis

    Lung cancer (LC) is among the most malignant cancers in the global, which has the highest mortality rate [ 1 ]. There are two classes of LC, small cell LC (SCLC) and non-small cell LC (NSCLC). NSCLC leads to 80–85% LC [ 2 , 3 ]. In the past two …

  17. Open Access 01-12-2024 | NSCLC | OriginalPaper

    Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

    Lung cancer is a highly prevalent and deadly disease. Previous research has shown that the incidence rate of non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) could reach as high as 50.5%[ 1 ]. NSCLC with …

  18. 16-04-2024 | Cytostatic Therapy | Online First

    Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis

    Lung cancer is a malignant tumor that originates from the bronchial glands or mucous membranes. Its morbidity and mortality rates are rapidly increasing, making it one of the most formidable malignancies affecting human health and life [ 1 ]. The …

  19. Open Access 01-03-2024 | NSCLC | ReviewPaper

    BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report

    BRAF mutations are found in 1–5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been confirmed that targeted therapy with dabrafenib + trametinib is effective in patients with metastatic …

  20. 21-03-2024 | NSCLC | Online First

    The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Lung cancer represents nearly 12% of total cancer diagnoses worldwide and continues to be the leading cause of cancer deaths. More than 2 million new cases were diagnosed in 2020, accounting for 18% of total cancer deaths worldwide [ 1 ]. In Spain …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.